Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP)‘s stock had its “buy” rating reiterated by analysts at Canaccord Genuity in a research report issued on Tuesday. They currently have a $22.00 price target on the stock. Canaccord Genuity’s price objective would suggest a potential upside of 108.14% from the company’s previous close.

Other equities research analysts have also issued reports about the company. Zacks Investment Research lowered Aquinox Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, August 15th. BidaskClub upgraded Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, August 4th. Cantor Fitzgerald reiterated a “buy” rating and set a $28.00 price target on shares of Aquinox Pharmaceuticals in a report on Thursday, November 9th. Needham & Company LLC reiterated a “buy” rating and set a $25.00 price target on shares of Aquinox Pharmaceuticals in a report on Thursday, November 9th. Finally, ValuEngine lowered Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, September 15th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. Aquinox Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $22.50.

Aquinox Pharmaceuticals (NASDAQ AQXP) traded down $0.54 on Tuesday, reaching $10.57. The company had a trading volume of 85,700 shares, compared to its average volume of 86,947. Aquinox Pharmaceuticals has a 12-month low of $10.20 and a 12-month high of $19.97.

COPYRIGHT VIOLATION WARNING: “Aquinox Pharmaceuticals, Inc. (AQXP) Stock Rating Reaffirmed by Canaccord Genuity” was originally posted by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright & trademark law. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/11/21/aquinox-pharmaceuticals-inc-aqxp-stock-rating-reaffirmed-by-canaccord-genuity.html.

Several hedge funds have recently modified their holdings of AQXP. Numeric Investors LLC acquired a new position in shares of Aquinox Pharmaceuticals during the fourth quarter worth approximately $2,319,000. Boxer Capital LLC bought a new stake in shares of Aquinox Pharmaceuticals during the fourth quarter valued at approximately $10,101,000. Franklin Resources Inc. increased its position in shares of Aquinox Pharmaceuticals by 7.6% during the first quarter. Franklin Resources Inc. now owns 1,245,945 shares of the company’s stock valued at $10,989,000 after purchasing an additional 87,600 shares during the period. BlackRock Inc. increased its position in shares of Aquinox Pharmaceuticals by 24.3% during the first quarter. BlackRock Inc. now owns 50,600 shares of the company’s stock valued at $446,000 after purchasing an additional 9,900 shares during the period. Finally, BlackRock Group LTD increased its position in shares of Aquinox Pharmaceuticals by 23.4% during the first quarter. BlackRock Group LTD now owns 200,100 shares of the company’s stock valued at $1,765,000 after purchasing an additional 37,900 shares during the period. Institutional investors own 95.51% of the company’s stock.

Aquinox Pharmaceuticals Company Profile

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.

Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.